BICALIEVA 50 MG

Rather than viewing Bicalutamide only as a member of the nonsteroidal androgen receptor antagonist class, its clinical role is better understood through the indications recorded here. Prostate cancer requiring androgen-deprivation therapy is the principal oncology use described in the database. Competitively blocks androgen binding to the androgen receptor. Hormone-pathway suppression is the central therapeutic principle, with treatment selection shaped by the prostate cancer disease state or other hormone-sensitive context described in the indication. The treatment is classified as Hormonal / Endocrine Therapy; Anti-Androgen and is associated with Prostate Cancer. Regimens listed include Bicalutamide + LHRH agonist/ADT; older combined androgen blockade regimens. These examples show where the medicine is incorporated into treatment pathways and, where relevant, which agents accompany it. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. Selection should remain anchored to the specific disease context, including any biomarker, receptor, stage, or previous-treatment criterion supplied with the indication. The pharmacologic mechanism provides context but does not by itself establish eligibility. This database entry is intended for clinical reference and not for individualized prescribing, dose selection, or treatment planning. Current product labeling and relevant guideline versions should be used to verify contemporary practice.